Bli medlem
Bli medlem

Du är här

2016-12-14

Recipharm AB: Recipharm bolsters development business with new appointments in the US and Europe

Recipharm, the contract development and manufacturing organisation
(CDMO), has appointed Anders Högdin and Aaron Small to lead the
growth of its pharmaceutical development services business in the US
and Europe.

Since forming in Sweden in 1995, Recipharm has experienced strong
year-on-year growth and is now operating from 20+ sites across 10
countries. In addition to its manufacturing services offering,
Recipharm delivers pharmaceutical development services from the early
discovery phase to supply of clinical trial materials from facilities
in Sweden, Italy, France, Israel and the US. Parallel to these new
appointments, Recipharm has strengthened the respective sales team in
order to create focus on customer management and new business
opportunities.

Based in Stockholm, Sweden, Anders Högdin will head the business
development and sales team within development services in Europe.
Anders has a MSc in chemistry and a PhD in organic chemistry from
Uppsala University. Before joining Recipharm in 2015, he was employed
at Syntagon, APL and OnTarget Chemistry in various roles.

Focused on driving the growth of the Recipharm's North American
business, Aaron Small will work in close contact with the Recipharm
facility in Research Triangle Park, North Carolina. Aaron has a BSc
in marketing and a Master of Business Administration and has been
part of Recipharm's business management function since 2012.

Commenting on the appointments, Carl-Johan Spak, Executive Vice
President, Global Technologies said: "Over the past year, Recipharm's
development business has continued to expand, with the integration of
new facilities, technologies and capabilities. The new North American
sales organisation will be extremely important for Recipharm as it
will enable the company to attract US customers to its extensive
network of development and manufacturing facilities outside of the
US".

"We are very pleased to have such skilled, ambitious and enthusiastic
professionals like Anders and Aaron to lead these two sales teams.
Their contributions will be extremely valuable in the development of
our business in offering new and existing customers access to our
world class contract development and manufacturing services."

Contact information
Carl-Johan Spak, Executive Vice President Global Technologies,
carl-johan.spak@recipharm.com, + 46 8 602 53 13

For media enquiries, please contact Lindsay Baldry at ramarketing:
lindsay@ramarketingpr.com,+ 44 (0)191 222 1242, ramarketingpr.com,
Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin:
/ramarketing

About Recipharm
Recipharm is a leading Contract Development and Manufacturing
Organisation (CDMO) (in the pharmaceutical industry employing around
3,500 employees. Recipharm offers manufacturing services of
pharmaceuticals in various dosage forms, production of clinical trial
material and APIs, and pharmaceutical product development. Recipharm
manufactures several hundred different products to customers ranging
from big pharma to smaller research and development companies.
Recipharm's turnover is approximately SEK 5.0 billion and the Company
operates development and manufacturing facilities in France, Germany,
India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and
is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B)
is listed on Nasdaq Stockholm.

For more information on Recipharm and its services, please visit
www.recipharm.com

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03

www.recipharm.com (https://www.recipharm.com/)
-----------------------------------------------------------
http://news.cision.com/recipharm-ab/r/recipharm-bolsters-development-bus...
http://mb.cision.com/Main/9273/2149848/603692.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.